{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-006898","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.894974+00:00","generated_at":"2026-05-25T00:36:20.118445+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OPKO Health to sell oncology testing assets to Labcorp for up to $225M","bullets":["Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.","Divested assets generate ~$85-100M in annual revenue; deal expected to close H2 2025.","BioReference retains core NY/NJ clinical testing and 4Kscore franchise (~$300M 2024 revenue).","Labcorp expects acquisition to be accretive to earnings in year one.","Transaction includes customary closing conditions and state regulatory approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-006898","json":"https://secwatch.observer/filing/0001437749-25-006898.json","markdown":"https://secwatch.observer/filing/0001437749-25-006898.md","text":"https://secwatch.observer/filing/0001437749-25-006898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774925006898/0001437749-25-006898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774925006898/opk20250305c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:36:20.118445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}